Related Experiment Videos
Ciclosporin in Goodpasture's syndrome
S Quérin1, W Schürch, R Beaulieu
1Department of Medicine, Hôtel-Dieu de Montréal Hospital, Montréal, Québec, Canada.
Insights
This case study shows ciclosporin effectively treated a patient with Goodpasture's syndrome when standard therapies failed. Ciclosporin helped stabilize kidney function and resolve hemoptysis, offering a new treatment option.
Area of Science:
- Nephrology
- Immunology
- Internal Medicine
Background:
- Goodpasture's syndrome is a rare autoimmune disorder characterized by glomerulonephritis and pulmonary hemorrhage.
- Standard treatment involves immunosuppressants like prednisone and cyclophosphamide, along with plasma exchange.
Observation:
- A 39-year-old male patient with Goodpasture's syndrome experienced worsening kidney function (serum creatinine up to 10.3 mg/dl) and recurrent hemoptysis despite standard therapy.
- Ciclosporin was initiated at 6 mg/kg/day.
Findings:
- Following the introduction of ciclosporin, the patient's serum creatinine levels began to decrease within two weeks.
- Serum creatinine stabilized at approximately 2.0 mg% (182 mumol/l), indicating improved renal function.
- Recurrent hemoptysis also resolved, suggesting efficacy in managing both renal and pulmonary manifestations.
Implications:
- This case suggests ciclosporin may be a valuable therapeutic option for Goodpasture's syndrome, particularly in refractory cases.
- Further research into ciclosporin's role in managing autoimmune glomerular diseases is warranted.
- Ciclosporin offers a potential alternative for patients unresponsive to conventional immunosuppressive treatments.
Abstract:
We report the case of a 39-year-old male patient with Goodpasture's syndrome. Despite therapy with prednisone, cyclophosphamide and plasma exchanges, serum creatinine (Scr) progressively increased up to 10.3 mg/dl (936 mumol/l) and hemoptysis recurred 3 months after initiation of treatment. Ciclosporin (CS) starting at 6 mg/kg/day was given. Scr began to decrease 2 weeks later and eventually stabilized at approximately 2.0 mg% (182 mumol/l). This case illustrates one of the potential uses of CS in human glomerular disease.